The mammalian molybdenum enzymes of mARC
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605507783 | ||
| 003 | CHVBK | ||
| 005 | 20210128100633.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150301xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00775-014-1216-4 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00775-014-1216-4 | ||
| 245 | 0 | 4 | |a The mammalian molybdenum enzymes of mARC |h [Elektronische Daten] |c [Gudrun Ott, Antje Havemeyer, Bernd Clement] |
| 520 | 3 | |a The "mitochondrial amidoxime reducing component” (mARC) is the most recently discovered molybdenum-containing enzyme in mammals. All mammalian genomes studied to date contain two mARC genes: MARC1 and MARC2. The proteins encoded by these genes are mARC-1 and mARC-2 and represent the simplest form of eukaryotic molybdenum enzymes, only binding the molybdenum cofactor. In the presence of NADH, mARC proteins exert N-reductive activity together with the two electron transport proteins cytochrome b5 type B and NADH cytochrome b5 reductase. This enzyme system is capable of reducing a great variety of N-hydroxylated substrates. It plays a decisive role in the activation of prodrugs containing an amidoxime structure, and in detoxification pathways, e.g., of N-hydroxylated purine and pyrimidine bases. It belongs to a group of drug metabolism enzymes, in particular as a counterpart of P450 formed N-oxygenated metabolites. Its physiological relevance, on the other hand, is largely unknown. The aim of this article is to summarize our current knowledge of these proteins with a special focus on the mammalian enzymes and their N-reductive activity. | |
| 540 | |a SBIC, 2014 | ||
| 690 | 7 | |a mARC |2 nationallicence | |
| 690 | 7 | |a Moco |2 nationallicence | |
| 690 | 7 | |a MOSC |2 nationallicence | |
| 690 | 7 | |a Biotransformation |2 nationallicence | |
| 690 | 7 | |a Amidoxime |2 nationallicence | |
| 690 | 7 | |a Cyt b5 : Cytochrome b5 type B |2 nationallicence | |
| 690 | 7 | |a Cyt b5 R : NADH cytochrome b5 reductase |2 nationallicence | |
| 690 | 7 | |a mARC : Mitochondrial amidoxime reducing component |2 nationallicence | |
| 690 | 7 | |a Moco : Molybdenum cofactor |2 nationallicence | |
| 690 | 7 | |a MOSC : Moco-sulfurase C-terminal domain |2 nationallicence | |
| 690 | 7 | |a mPTS : Peroxisomal membrane targeting signal |2 nationallicence | |
| 690 | 7 | |a NO : Nitric oxide |2 nationallicence | |
| 690 | 7 | |a NOHA : N ω-hydroxy-l-arginine |2 nationallicence | |
| 690 | 7 | |a SO : Sulfite oxidase |2 nationallicence | |
| 690 | 7 | |a SNP : Single-nucleotide polymorphism |2 nationallicence | |
| 690 | 7 | |a XO : Xanthine oxidase |2 nationallicence | |
| 700 | 1 | |a Ott |D Gudrun |u Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstraße 76, 24118, Kiel, Germany |4 aut | |
| 700 | 1 | |a Havemeyer |D Antje |u Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstraße 76, 24118, Kiel, Germany |4 aut | |
| 700 | 1 | |a Clement |D Bernd |u Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstraße 76, 24118, Kiel, Germany |4 aut | |
| 773 | 0 | |t JBIC Journal of Biological Inorganic Chemistry |d Springer Berlin Heidelberg |g 20/2(2015-03-01), 265-275 |x 0949-8257 |q 20:2<265 |1 2015 |2 20 |o 775 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00775-014-1216-4 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00775-014-1216-4 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ott |D Gudrun |u Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstraße 76, 24118, Kiel, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Havemeyer |D Antje |u Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstraße 76, 24118, Kiel, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Clement |D Bernd |u Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstraße 76, 24118, Kiel, Germany |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t JBIC Journal of Biological Inorganic Chemistry |d Springer Berlin Heidelberg |g 20/2(2015-03-01), 265-275 |x 0949-8257 |q 20:2<265 |1 2015 |2 20 |o 775 | ||